Skip to main content
OpenTrials
Completed

NCT Number: NCT04570488

Predicting Favorable Outcomes in Hospitalized Covid-19 Patients

Testing use of predictive analytics to predict which COVID-19+ patients are at low risk for an adverse event (ICU transfer, intubation, mortality, hospice discharge, re-presentation to the ED, oxygen requirements exceeding nasal cannula at 6L/Min) in the next 96 hours

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID Adverse Event Corona Virus Infection Coronaviridae Infections Coronavirus Infections Infections Nidovirales Infections RNA Virus Infections Virus Diseases

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

NYU Langone Health

New York, 10016, United States

About this study

To assess if display of low risk of adverse event in EPIC can safely reduce length of stay and plan for discharge.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult hospitalized COVID19+ patients predicted to have no adverse event at 96 events with a threshold at 90% PPV, with at least one low risk during their admission who are discharged alive and have not been in the ICU

Exclusion criteria

Age < 18 years not hospitalized for COVID19+.

Treatment and study plan

EPIC risk score display

Other

Display of risk score/ colored flag in Epic patient list column

Primary outcomes

  1. Reduction in days from first low-risk score to discharge

    Time frame: 96 Hours

    Reduction in days from first low-risk score to discharge

Secondary outcomes

  1. Reduction in length of stay (LOS)

    Time frame: 96 hours

    Reduction in LOS for green patients that have not been in the ICU

  2. Reduction in GTD vs. LOS

    Time frame: 96 hours

    Reduction in GTD vs. LOS for all green patients discharged alive vs all patients discharged alive

  3. No change in 30 day re-ED presentation or hospital admission rate for cohort

    Time frame: 96 hours

    No change in 30 day re-ED presentation or hospital admission rate for cohort

Other outcomes

  1. Re-presentation to ED

    Time frame: 96 hours

  2. Readmission to hospital

    Time frame: 96 hours

  3. Mortality

    Time frame: 96 hours

  4. Postdischarge mortality

    Time frame: 96 hours

Sponsors and collaborators

Lead sponsor

NYU Langone Health

Other

Registry information

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Sep 30, 2020
Registry last updated
Dec 27, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.